Skp2 is a promising therapeutic target in breast cancer

Zhiwei Wang, Hidefumi Fukushima, Hiroyuki Inuzuka, Lixin Wan, Pengda Liu, Daming Gao, Fazlul H. Sarkar, Wenyi Wei

Research output: Contribution to journalReview articlepeer-review

52 Citations (Scopus)

Abstract

Breast cancer is the most common type of cancer among American women, and remains the second leading cause of cancer-related death for female in the United States. It has been known that several signaling pathways and various factors play critical roles in the development and progression of breast cancer, such as estrogen receptor, Notch, PTEN, human epidermal growth factor receptor 2, PI3K/Akt, BRCA1, and BRCA2. Emerging evidence has shown that the F-box protein S-phase kinase associated protein 2 (Skp2) also plays an important role in the pathogenesis of breast cancer. Therefore, in this brief review, we summarize the novel functions of Skp2 in the pathogenesis of breast cancer. Moreover, we provide further evidence regarding the state of our knowledge toward the development of novel Skp2 inhibitors especially natural "chemopreventive agents" as targeted approach for the prevention and/or treatment of breast cancer.

Original languageEnglish
Article number00057
JournalFrontiers in Oncology
Volume1
Issue numberJAN
DOIs
Publication statusPublished - 2012

Keywords

  • Breast cancer
  • Cell cycle
  • Signaling pathway
  • Skp2
  • Therapy
  • Ubiquitination

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Skp2 is a promising therapeutic target in breast cancer'. Together they form a unique fingerprint.

Cite this